The relationship between drug price and purity and population level harm

Pink and white pills

In illicit drug markets, the price and purity of drugs change frequently. While it is well known that purity-adjusted price affects drug use, impacts on other outcomes are less clear. This rapid review examines the relationship between price, purity and seven population level measures of drug-related harm and any differences across three drug types. With a few exceptions, it found an inverse relationship between purity-adjusted price and drug-related harm, with higher purity-adjusted price associated with less drug-related harm, and lower purity-adjusted price associated with increased harm. This shows the value of price and purity data for predicting drug market impacts and the importance of improving price and purity data collection and analyses, particularly in Australia.


URLs correct as at February 2024

Australian Criminal Intelligence Commission (ACIC) 2019. Illicit drug data report 2017–18. Canberra: Australian Criminal Intelligence Commission.

Babor T, Caulkins J, Fischer B, Foxcroft D, Humphreys K, Medina-Mora ME et al. 2018. Drug policy and the public good, 2nd ed. Oxford: Oxford University Press

Bach PB & Lantos J 1999. Methadone dosing, heroin affordability, and the severity of addiction. American Journal of Public Health 89(5): 662–65

Bright DA & Ritter A 2010. Retail price as an outcome measure for the effectiveness of drug law enforcement. International Journal of Drug Policy 21(5): 359–63

Brunt TM, van Laar M, Niesink RJM & van den Brink W 2010. The relationship of quality and price of the psychostimulants cocaine and amphetamine with health care outcomes. Drug and Alcohol Dependence, 111(1–2): 21–29

Callaghan RC, Cunningham JK, Victor JC & Liu LM 2009. Impact of Canadian federal methamphetamine precursor and essential chemical regulations on methamphetamine-related acute-care hospital admissions. Drug and Alcohol Dependence 105(3): 185–93

Caulkins JP 2007. Price and purity analysis for illicit drug: Data and conceptual issues. Drug and Alcohol Dependence 90: S61–S68

Caulkins JP 2001. Drug prices and emergency department mentions for cocaine and heroin. American Journal of Public Health 91(9): 1446–48

Caulkins JP 1994. Developing price series for cocaine. RAND Monograph Series MR317. Santa Monica: RAND Corporation

Caulkins JP, Rajderkar SS & Vasudev S 2010. Creating price series without price data: Harnessing the power of forensic data. In B Kilmer & S Hoorens (eds), Understanding illicit drug markets, supply-reduction efforts, and drug-related crime in the European Union. Cambridge: RAND: 165–96

Caulkins JP & Reuter P 1998. What price data tell us about drug markets. Journal of Drug Issues 28(3): 593–612

Ciccarone D, Unick GJ, Cohen JK, Mars SG & Rosenblum D 2016. Nationwide increase in hospitalizations for heroin-related soft tissue infections: Associations with structural market conditions. Drug and Alcohol Dependence 163: 126–33

Cunningham JK & Liu LM 2008. Impact of methamphetamine precursor chemical legislation, a suppression policy, on the demand for drug treatment. Social Science & Medicine 66(7): 1463–73

Cunningham JK & Liu LM 2005. Impacts of federal precursor chemical regulations on methamphetamine arrests. Addiction 100(4): 479–88

Cunningham JK & Liu LM 2003. Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine‐related hospital admissions. Addiction 98(9): 1229–37

Cunningham JK, Liu LM & Callaghan RC 2009. Impact of US and Canadian precursor regulation on methamphetamine purity in the United States. Addiction 104(3): 441–53

Darke S, Hall W, Weatherburn D & Lind B 1999. Fluctuations in heroin purity and the incidence of fatal heroin overdose. Drug and Alcohol Dependence 54(2): 155–61

Dave D 2006. The effects of cocaine and heroin price on drug-related emergency department visits. Journal of Health Economics 25(2): 311–33

Davies RB 2010. Mandatory minimum sentencing, drug purity and overdose rates. Economic and Social Review 41(4): 429–57

Day C 2004a. Documenting the heroin shortage: Australia. In L Degenhardt, C Day & W Hall (eds), The causes, course and consequences of the heroin shortage in Australia. Canberra: National Drug Law Enforcement Research Fund.

Day C 2004b. Documenting the heroin shortage: New South Wales. In L Degenhardt, C Day & W Hall (eds), The causes, course and consequences of the heroin shortage in Australia. Canberra: National Drug Law Enforcement Research Fund.

Degenhardt L, Conroy E, Day C, Gilmour S & Hall W 2005a. The impact of a reduction in drug supply on demand for and compliance with treatment for drug dependence. Drug and Alcohol Dependence 79(2): 129–35

Degenhardt L, Conroy E, Gilmour S & Collins L 2005b. The effect of a reduction in heroin supply in Australia upon drug distribution and acquisitive crime. British Journal of Criminology 45(1): 2–24

Degenhardt L, Conroy E, Gilmour S & Hall W 2005c. The effect of a reduction in heroin supply on fatal and non‐fatal drug overdoses in New South Wales, Australia. Medical Journal of Australia 182(1): 20–23

Degenhardt L, Day C, Conroy E, Gilmour S & Hall W 2005d. Age differentials in the impacts of reduced heroin: effects of a “heroin shortage” in NSW, Australia. Drug and Alcohol Dependence 79(3): 397–404

Degenhardt L, Day C, Dietze P, Pointer S, Conroy E, Collins L & Hall W 2005e. Effects of a sustained heroin shortage in three Australian States. Addiction 100(7): 908–20

Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall W et al. 2013. Global burden of disease attributable to illicit drug use and dependence: Findings from the Global Burden of Disease Study 2010. The Lancet 382(9904): 1564–74

DeSimone J 2001. The effect of cocaine prices on crime. Economic Inquiry 39(4): 627–43

Dobkin C & Nicosia N 2009. The war on drugs: methamphetamine, public health, and crime. American Economic Review 99(1): 324–49

European Monitoring Centre for Drugs and Drug Addiction 2018. European drug report 2018: Trends and developments. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction

European Monitoring Centre for Drugs and Drug Addiction & Europol 2018. Improved drug supply indicators for Europe: Progress report. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction & Europol

Gallet CA 2014. Can price get the monkey off our back? A meta‐analysis of illicit drug demand. Health Economics 23(1): 55–68

Ganann R, Ciliska D & Thomas H 2010. Expediting systematic reviews: Methods and implications of rapid reviews. Implementation Science 5(1): 56

Hughes C, Ritter A, Cowdery N & Phillips B 2014. Evaluating Australian drug trafficking thresholds: Proportionate, equitable and just? Canberra: Criminology Research Advisory Council.

Hyatt Jr RR & Rhodes W 1995. The price and purity of cocaine: The relationship to emergency room visits and death, and to drug use among arrestees. Statistics in Medicine 14(5‐7): 655–68

Karlsson A & Burns L 2018. Australian Drug Trends 2017: Findings from the Illicit Drug Reporting System (IDRS). Sydney: National Drug and Alcohol Research Centre, University of New South Wales

Longo MC, Henry-Edwards SM, Humeniuk RE, Christie P & Ali RL 2004. Impact of the heroin ‘drought’ on patterns of drug use and drug-related harms. Drug and Alcohol Review 23(2): 143–50

Mattick RP, Topp L & Degenhardt L 2004. A reduction in the availability of heroin in Australia. Bulletin on Narcotics 56(1-2): 65–88

Moore T 2007. Working estimates of the social costs per gram and per user for cannabis, cocaine, opiates and amphetamines. Drug Policy Modelling Program monograph series no. 14. Sydney: National Drug and Alcohol Research Centre, University of New South Wales

Moore T, Caulkins JP, Ritter A, Dietze P, Monagle S & Pruden J 2005. Heroin markets in Australia: Current understandings and future possibilities. Drug Policy Modelling Program monograph series no. 9. Fitzroy: Turning Point Alcohol and Drug Centre

Nonnemaker J, Engelen M & Shive D 2011. Are methamphetamine precursor control laws effective tools to fight the methamphetamine epidemic? Health Economics 20(5): 519–31

Patterson E, Sullivan T & Bricknell S 2019. Drug use monitoring in Australia: Drug use among police detainees, 2017. Statistical Report no. 14. Canberra: Australian Institute of Criminology.

Peacock A, Gibbs D, Karlsson A, Uporova J, Sutherland R, Bruno R et al. 2018. Australian Drug Trends 2018: Key findings from the National Ecstasy and Related Drugs Reporting System (EDRS) Interviews. Sydney: National Drug and Alcohol Research Centre, University of New South Wales

Reuter P & Kleiman MA 1986. Risks and prices: An economic analysis of drug enforcement. Crime and Justice 7: 289–340

Rhodes W, Johnston P, Han S, McMullen Q & Hozik L 2000. Illicit drugs: Price elasticity of demand and supply. Abt Associates

Risser D, Uhl A, Oberndorfer F, Hönigschnabl S, Stichenwirth M, Hirz R et al. 2007. Is there a relationship between street heroin purity and drug-related emergencies and/or drug-related deaths? An analysis from Vienna, Austria. Journal of Forensic Sciences 52(5): 1171–1176

Ritter A, Chalmers J & Gomez M 2019. Measuring unmet demand for alcohol and other drug treatment: The application of an Australian population-based planning model. Journal of Studies on Alcohol and Drugs, Supplement, (s18), 42-50.

Ritter A, Mellor R, Chalmers J, Sunderland M & Lancaster K 2019. Key considerations in planning for substance use treatment: Estimating treatment need and demand. Journal of Studies on Alcohol and Drugs Supplement 18: 22–30

Rosenblum D, Unick J & Ciccarone D 2017. An instrumental variables approach to estimating the effects of changes in the heroin market on overdose in the US. Working paper no. 170011. Canadian Centre for Health Economics

Schifano F & Corkery J 2008. Cocaine/crack cocaine consumption, treatment demand, seizures, related offences, prices, average purity levels and deaths in the UK (1990–2004). Journal of Psychopharmacology 22(1): 71–79

Scott N, Caulkins JP, Ritter A, Quinn C & Dietz P 2014. High-frequency drug purity and price series as tools for explaining drug trends and harms in Victoria, Australia. Addiction 110(1): 120–28

Smithson M, McFadden M, Mwesigye SE & Casey T 2004. The impact of illicit drug supply reduction on health and social outcomes: The heroin shortage in the Australian Capital Territory. Addiction 99(3): 340–48

Toprak S & Cetin I 2009. Heroin overdose deaths and heroin purity between 1990 and 2000 in Istanbul, Turkey. Journal of Forensic Sciences 54(5): 1185–88

Unick G, Rosenblum D, Mars S & Ciccarone D 2014. The relationship between US heroin market dynamics and heroin-related overdose, 1992–2008. Addiction 109(11): 1889–98

United Nations Office on Drugs and Crime 2018. World drug report 2018. Vienna: United Nations Office on Drugs and Crime

Weatherburn D, Jones C, Freeman K & Makkai T 2003. Supply control and harm reduction: Lessons from the Australian heroin ‘drought’. Addiction 98(1): 83–91

Weatherburn D & Lind B 1997. The impact of law enforcement activity on a heroin market. Addiction 92(5): 557–69

Weatherburn D, Lind B, Dubow Y & Jochelson R 1995. Drug law enforcement policy and its impact on the heroin market. Sydney: New South Wales Bureau of Crime Statistics and Research

Zhu H, Wilson FA, Stimpson JP & Pagán JA 2014. Correlation between cocaine prices and purity with trends in emergency department visits in a major metropolitan area. Journal of Urban Health 91(5): 1009–18